[8-K] Applied Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Applied Therapeutics, Inc. disclosed that Nasdaq notified the company its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days, triggering an initial compliance period. Nasdaq has now granted an additional 180-calendar-day extension to regain compliance with the $1.00 bid-price requirement, extending the deadline to February 2, 2026. In connection with the extension, the company’s listing will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025. The Extension Notice does not immediately affect the listing, and the company says it will monitor the bid price and consider available options, including a reverse stock split, to attempt to regain compliance. If the bid price reaches at least $1.00 for 10 consecutive business days before the deadline, Nasdaq will confirm compliance; otherwise Nasdaq may initiate delisting procedures and the company could appeal.

Positive

• Nasdaq granted an additional 180-calendar-day extension to regain compliance, extending the cure period to February 2, 2026
• Listing remains on Nasdaq and the Extension Notice has no immediate effect on the trading of the Common Stock

Negative

• Closing bid price was below $1.00 for 30 consecutive business days, triggering the initial deficiency notice
• Listing will transfer from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025
• Risk of delisting remains if the company does not regain compliance by February 2, 2026

Insights

Securities Analyst

TL;DR: Nasdaq gave APLT more time to meet the $1.00 bid-price rule; extension delays delisting but signals near-term marketability risk.

The extension to February 2, 2026 provides a meaningful runway to correct the bid-price deficiency without immediate delisting, preserving trading on Nasdaq. However, transfer to the Nasdaq Capital Market is a class downgrade in listing tier and may reduce visibility and liquidity. The explicit 10-consecutive-business-day cure condition means the company needs sustained price improvement rather than transient upticks. Management’s mention of a reverse split is a typical remedial option, but such corporate actions can have mixed investor reception and require careful timing and communication.

Corporate Governance Expert

TL;DR: The Nasdaq extension buys governance time but highlights continued market-price pressure and potential impacts on capital access.

The formal notice documents a regulatory deficiency that the board and management must address through investor relations, potential capital strategy adjustments, or structural actions such as a reverse split. The transfer to the Nasdaq Capital Market is procedural but sends a public signal about the company’s market standing. The company retains procedural rights, including the right to appeal any future delisting determination, which preserves governance options while the firm seeks to restore compliance.

false000169753200016975322025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Applied Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38898	81-3405262
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
545 Fifth Avenue, Suite 1400
New York, New York				10017
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 212 220-9226

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001		APLT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously reported, on February 7, 2025, Applied Therapeutics, Inc. (the “Company”) received a notification letter (the “Bid Price Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), has been below the minimum $1.00 per share required (the “Bid Price Requirement”) for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was given 180 calendar days, or until August 6, 2025, to regain compliance with the Bid Price Requirement pursuant to Nasdaq Listing Rule 5450(a)(1).

On August 13, 2025, the Company received a notice (the “Extension Notice”) from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until February 2, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective as of August 15, 2025. The Extension Notice has no other immediate effect on the listing of the Common Stock.

The Company intends to continue actively monitor the bid price for its Common Stock between now and February 2, 2026, and will consider available options to resolve the deficiency and regain compliance with the Bid Price Requirement. These options include, but are not limited to, effecting a reverse stock split, if necessary, to attempt to regain compliance. If at any time before February 2, 2026, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the Bid Price Requirement. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There is no assurance, however, that the Company will regain compliance with the Bid Price Requirement or that the Common Stock will not be delisted from Nasdaq.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APPLIED THERAPEUTICS, INC.
Date:	August 14, 2025	By:	/s/ Les Funtleyder
			Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer

FAQ

What did Applied Therapeutics (APLT) disclose about Nasdaq listing compliance?

The company disclosed that Nasdaq notified it the closing bid price was under the $1.00 minimum and Nasdaq granted an additional 180-calendar-day extension to regain compliance.

What is the deadline for APLT to regain compliance with Nasdaq's bid-price requirement?

Nasdaq set a new deadline of February 2, 2026 for the company to meet the $1.00 bid-price requirement.

Will APLT be delisted immediately from Nasdaq?

No. The Extension Notice does not have any immediate effect on the listing; the company was given additional time to regain compliance.

What happens if APLT's stock price meets the requirement before the deadline?

If the closing bid price is at least $1.00 for 10 consecutive business days before February 2, 2026, Nasdaq will provide written confirmation that the company has regained compliance.

What remedial actions did the company say it may consider?

The company said it will consider available options to resolve the deficiency, including a reverse stock split if necessary.